- 体外研究：
- MHY1485 induces mTOR activity, which is another regulator of autophagy. MHY1485 markedly increases the LC3II/LC3I ratio dose-dependently and time-dependently[1]. An mTOR activator MHY1485 stimulates mTOR, S6K1 and rpS6 phosphorylation. Treatment with MHY1485 increases phospho-mTOR levels without affecting total mTOR content. MHY1485 treatment also increases the phosphorylation of downstream S6K1 and rpS6 proteins without affecting total S6K1 and rpS6 levels[2]. An mTOR activator, MHY1485, also abolishes the inhibitory effect of liraglutide on osteoblastic differentiation, and results in p-mTOR and TGF-β downregulation, but does not attenuate the liraglutide-induced increase in p-AMPK protein expression levels. Co-treatment with 4 nM Liraglutide and 1 µM MHY1485, an mTOR activator, results in protein expression levels of Alp, OC, p-mTOR and TGF-β and matrix mineralization comparable to those of positive control cells cells[3].
- 简介：
- MHY1485 is mTOR activator that potently inhibits autophagy by suppression of fusion between autophagosomes and lysosomes.
- 特异性：
- Target: mTOR . Fields: MHY1485 is mTOR activator that potently inhibits autophagy by suppression of fusion between autophagosomes and lysosomes.
- 储存：
- 2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO
.png)
.png)
.png)